Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITCI NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/AJNJJohnson & Johnson$177.10+0.9%$165.99$140.68▼$181.16$422.54B0.418.40 million shs6.94 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+81.21%JNJJohnson & Johnson-0.67%-1.90%+4.45%+13.23%+7.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITCIIntra-Cellular Therapies0.8642 of 5 stars1.10.00.04.50.01.70.6JNJJohnson & Johnson4.8178 of 5 stars2.35.04.23.93.51.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITCIIntra-Cellular Therapies 2.20Hold$118.00-10.52% DownsideJNJJohnson & Johnson 2.65Moderate Buy$176.29-0.46% DownsideCurrent Analyst Ratings BreakdownLatest JNJ and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$185.00 ➝ $200.007/23/2025JNJJohnson & JohnsonErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy7/17/2025JNJJohnson & JohnsonPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight7/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $176.007/17/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $185.007/17/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$180.00 ➝ $190.007/17/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$164.00 ➝ $167.007/17/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$161.00 ➝ $175.007/17/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$171.00 ➝ $176.007/10/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44JNJJohnson & Johnson$88.82B4.80$13.25 per share13.37$32.58 per share5.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/AJNJJohnson & Johnson$14.07B$9.3518.9416.002.2325.00%32.49%13.00%10/21/2025 (Estimated)Latest JNJ and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.94%N/A55.61%64 YearsLatest JNJ and ITCI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITCIIntra-Cellular TherapiesN/A7.667.51JNJJohnson & Johnson0.501.010.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITCIIntra-Cellular Therapies92.33%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipITCIIntra-Cellular Therapies2.60%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJ and ITCI HeadlinesRecent News About These CompaniesJudge deals Johnson & Johnson $442M catheter suit blow with denied motion, injunction3 hours ago | massdevice.comJohnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program3 hours ago | aol.comAJ&J Ends Imaavy Development in Rheumatoid Arthritis Post Study FailureAugust 29 at 12:16 PM | zacks.comJohnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on ItAugust 29 at 10:00 AM | zacks.comJohnson & Johnson Ends Rheumatoid Arthritis Drug Combo ProgramAugust 29 at 7:50 AM | benzinga.comJohnson & Johnson $JNJ Shares Sold by Lansforsakringar Fondforvaltning AB publAugust 29 at 7:16 AM | marketbeat.comJohnson & Johnson $JNJ Shares Purchased by OMERS ADMINISTRATION CorpAugust 29 at 6:53 AM | marketbeat.comHow Is Johnson & Johnson’s Stock Performance Compared to Other Healthcare Stocks?August 29 at 3:11 AM | barchart.comJ&J drops development of combination arthritis drugAugust 28 at 5:13 PM | reuters.comJohnson & Johnson $JNJ Shares Sold by D L Carlson Investment Group Inc.August 28 at 8:36 AM | marketbeat.comTruvestments Capital LLC Grows Stock Position in Johnson & Johnson $JNJAugust 28 at 8:34 AM | marketbeat.comB. Metzler seel. Sohn & Co. AG Buys 6,407 Shares of Johnson & Johnson $JNJAugust 28 at 8:10 AM | marketbeat.comGuggenheim Capital LLC Raises Stake in Johnson & Johnson $JNJAugust 28 at 7:36 AM | marketbeat.comJohnson & Johnson $JNJ Stake Raised by CreativeOne Wealth LLCAugust 28 at 7:35 AM | marketbeat.comIeq Capital LLC Raises Stake in Johnson & Johnson $JNJAugust 28 at 7:13 AM | marketbeat.comRedwood Investment Management LLC Acquires 3,599 Shares of Johnson & Johnson $JNJAugust 28 at 6:33 AM | marketbeat.comGamco Investors INC. ET AL Reduces Stock Position in Johnson & Johnson $JNJAugust 28 at 6:33 AM | marketbeat.comFORA Capital LLC Lowers Position in Johnson & Johnson $JNJAugust 28 at 6:13 AM | marketbeat.comJump Financial LLC Reduces Stake in Johnson & Johnson $JNJAugust 28 at 5:19 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Trading Down 1.1% - Time to Sell?August 27 at 2:10 PM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Samalin Investment Counsel LLCAugust 27 at 8:38 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Worried About a Fading Rally? Consider These 3 Dividend StocksBy Dan Schmidt | August 11, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025JNJ and ITCI Company DescriptionsIntra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Johnson & Johnson NYSE:JNJ$177.10 +1.65 (+0.94%) Closing price 03:59 PM EasternExtended Trading$177.46 +0.36 (+0.20%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access